{"id":1422,"date":"2019-10-25T17:28:19","date_gmt":"2019-10-25T15:28:19","guid":{"rendered":"http:\/\/galpharma.tn\/medicament\/cholestyl\/"},"modified":"2023-11-20T09:11:22","modified_gmt":"2023-11-20T08:11:22","slug":"cholestyl","status":"publish","type":"medicament","link":"https:\/\/galpharma.tn\/en\/medicaments\/cholestyl\/","title":{"rendered":"CHOLESTYL"},"content":{"rendered":"<ul>\n<li>Reduction of pure hypercholesterolemia (type Ila) or mixed (type IIb and III) in addition to an adapted and diligent diet.<\/li>\n<li>Reduction of coronary events in hypertensive patients treated with 3 risk factors in primary prevention, with or without associated hyperlipidaemia.<\/li>\n<li>Prevention of coronary and cerebra vascular events in type 2 diabetic patients with another risk factor, with or without associated hyperlipidaemia.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Reduction of pure hypercholesterolemia (type Ila) or mixed (type IIb and III) in addition to an adapted and diligent diet. Reduction of coronary events in hypertensive patients treated with 3 risk factors in primary prevention, with or without associated hyperlipidaemia. Prevention of coronary and cerebra vascular events in type 2 diabetic patients with another risk [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"template":"","class_list":["post-1422","medicament","type-medicament","status-publish","hentry","dci-atorvastatin","class_therapeutique-metabolism-and-nutrition","class_therapeutique-alphaglucosidase-inhibitor","galenique-tablets"],"_links":{"self":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/medicament\/1422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/medicament"}],"about":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/types\/medicament"}],"wp:attachment":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/media?parent=1422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}